Welcome to our dedicated page for Tscan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on Tscan Therapeutics stock.
TScan Therapeutics, Inc. (NASDAQ: TCRX) is a pioneering biopharmaceutical company focused on developing advanced T-cell receptor (TCR) engineered T cell therapies (TCR-T) aimed at treating cancer. Specializing in harnessing novel T cell systems, TScan is at the forefront of extending the promise of immunotherapy to patients with hematologic malignancies and solid tumors.
The company's leading therapies, TSC-100 and TSC-101, are designed to eliminate residual leukemia and prevent relapse in patients with blood cancers such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) undergoing hematopoietic stem cell transplantation. These liquid tumor TCR-T therapy candidates are currently in development, reflecting TScan's commitment to improving patient outcomes.
TScan is also developing multiplexed TCR-T therapy candidates for treating various solid tumors, showcasing the company's versatility and innovative approach in the immunotherapy landscape. Recent recognition includes the RMAT designation granted for both TSC-100 and TSC-101, highlighting their potential significance in cancer treatment.
In addition to its groundbreaking therapeutic developments, TScan Therapeutics maintains strong partnerships and a robust financial foundation. The company frequently updates its stakeholders through transparent communication and investor relations, ensuring that all relevant developments and milestones are promptly shared.
For the latest news and updates, you can contact Heather Savelle, VP of Investor Relations, at 857-399-9840 or via email at hsavelle@tscan.com. Further inquiries can also be directed to Joyce Allaire, Managing Director at LifeSci Advisors, LLC, at 617-435-6602 or jallaire@lifesciadvisors.com.
TScan Therapeutics (Nasdaq: TCRX) announced the publication of a peer-reviewed article in Cell, showcasing its screening technology that identifies T cell targets in head and neck cancer patients undergoing immunotherapy. The study revealed the TCR engineered candidate TSC-204-C07 targeting MAGE-A1. The research involved 29 patients and was a collaboration with Harvard institutions. TScan aims to file an IND for TSC-204-C07 in late 2022, alongside plans to develop multiplexed TCR therapies for solid tumors. The company positions itself for growth in TCR-T therapies.
TScan Therapeutics, Inc. (TCRX) has appointed Dr. Debora Barton as Chief Medical Officer, bringing nearly 20 years of clinical oncology experience. This appointment coincides with the upcoming Phase 1 trial for leukemia therapy, aimed at treating hematologic malignancies. Dr. Barton previously held key roles at Carisma Therapeutics and Iovance Biotherapeutics, overseeing clinical development and operations. TScan is focused on T-cell receptor engineered therapies, with lead candidates in development targeting both liquid and solid tumors.
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced its participation in a virtual fireside chat at the LifeSci 2nd Annual Genetic Medicines Symposium on June 28, 2022, at 9:00 a.m. ET. The event will focus on T-cell receptor (TCR) engineered therapies aimed at treating cancer. Interested parties can access a live webcast via the company’s website, with an archived replay available for 30 days post-event. TScan specializes in innovative TCR-T therapies, including candidates TSC-100 and TSC-101 targeting hematologic malignancies.
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biopharmaceutical company, will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 9:30 a.m. ET in New York. This event will focus on TCR engineered T cell therapies for cancer treatment. Interested parties can access the live webcast on the Company's website, with an archived replay available for 30 days post-event. TScan's lead therapies, TSC-100 and TSC-101, aim to treat hematologic malignancies and prevent leukemia relapse post-transplant.
TScan Therapeutics has announced the initiation of study start-up activities for its Phase 1 clinical trial involving TSC-100 and TSC-101, following FDA clearance of the investigational new drug (IND) application for TSC-101 targeting hematologic malignancies. This marks the second IND clearance for TScan’s leukemia program, aimed at reducing relapse risks after allogeneic hematopoietic cell transplantation. Preliminary data from the three arms of the trial are expected by the end of 2022.
TScan Therapeutics (TCRX) has identified its lead TCR-T cell therapy candidate, TCR-200-A02, for HPV-positive solid tumors, with an IND submission expected in 2H22. Additionally, TCR-204-C07 targets a novel MAGEA1 epitope, also on track for IND submission. Preclinical results show TCR-200-A02 exhibits strong cytotoxicity against HPV+ cell lines and no off-target activity. The multiplexing of TCRs demonstrates potential for enhanced anti-tumor effectiveness, overcoming tumor antigen heterogeneity. TScan will present further data at a virtual KOL event on May 19, 2022.
TScan Therapeutics (TCRX) announced participation in a virtual fireside chat at the H.C. Wainwright Global Investment Conference scheduled for May 24, 2022, at 7:00 a.m. ET. This event will focus on TCR engineered T cell therapies for cancer treatment. A live webcast will be accessible through the company’s website, and a replay will be available for 30 days afterward. The company specializes in TCR-T therapies targeting hematologic malignancies and solid tumors, leveraging its ImmunoBank of therapeutic TCRs.
TScan Therapeutics (Nasdaq: TCRX) has announced a virtual key opinion leader (KOL) event on May 19, 2022, at 4:30 p.m. ET. The event will discuss highlights from the American Society of Gene & Cell Therapy 25th Annual Meeting and TScan's solid tumor program. Featured speakers include Dr. Kai Wucherpfennig and TScan's executive team. Key topics will include TCR-T therapy candidates TSC-200-A02 and TSC-204-C07, addressing antigen heterogeneity. Registration details and replay options are available on TScan's website.
TScan Therapeutics (TCRX) announced its Q1 2022 financial results, reporting revenue of $3 million, up from $2 million YoY, attributed to its collaboration with Novartis. The company ended the quarter with $140.8 million in cash, sufficient to fund operations into 2024. TScan is set to initiate its Phase 1 umbrella trial for leukemia therapies TSC-100 and TSC-101 in Q2 2022, despite receiving a clinical hold on TSC-101 from the FDA. Future milestones include presenting clinical data by year-end and advancing its solid tumor TCR therapy candidates.
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced it will host a virtual KOL event on May 19, 2022, at 4:30 p.m. ET, discussing key presentations from the ASGCT Annual Meeting held from May 16-19, 2022. Three abstracts were accepted, focusing on innovative TCR-T cell therapies, including TSC-200-A02 for HPV-positive tumors, multiplexed therapies for solid tumors, and a novel TCR-T candidate for head and neck cancer. The company aims to advance its TCR-T candidates, which target multiple antigens to enhance cancer treatment efficacy.
FAQ
What is the current stock price of Tscan Therapeutics (TCRX)?
What is the market cap of Tscan Therapeutics (TCRX)?
What is TScan Therapeutics, Inc.?
What are TScan's leading therapy candidates?
What recent recognition has TScan's therapies received?
What types of cancer does TScan focus on?
How does TScan aim to improve cancer treatment?
How can I contact TScan's Investor Relations?
Where can I get the latest updates about TScan?
What is the stock symbol for TScan Therapeutics, Inc.?
Who are the key contacts for media inquiries at TScan?
What are TScan's goals in immunotherapy?
